Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007196
Chunk: 5

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 5
---
a Pharmaceuticals PLC and its consolidated subsidiaries.

For investors outside the United States: We have not taken any action to permit a public offering of the Depositary Shares outside the United States or to permit the possession or distribution of this prospectus outside the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about and observe any restrictions relating to the offering of the Depositary Shares and the distribution of this prospectus outside of the United States.

| 1 |

<div align='center'>PRESENTATION OF FINANCIAL AND OTHER INFORMATION</div>

Our
financial statements are prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting
Standards Board. We have made rounding adjustments to some of the figures included in this prospectus. Accordingly, numerical figures
shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them.

We
prepare our consolidated financial statements in British pounds sterling. Except as otherwise stated, all monetary amounts in this prospectus
are presented in British pounds sterling.

In this prospectus, unless
otherwise specified or the context otherwise requires:

| · | “$” and “U.S. dollar” each refer to the United States dollar (or units thereof); 
 and                                                                              |

| · | “£,” “pence” and “p” each refer to the British pound sterling 
 (or units thereof).                                           |

On March 27, 2023, following shareholder approval, we effected a one-for-20 reverse
split of our Ordinary Shares and our Ordinary Shares began trading on AIM, a market operated by the London Stock Exchange plc, or AIM,
on a split-adjusted basis as of such date. No fractional shares were issued in connection with the reverse stock split. On March 24, 2023,
our shareholders approved the cancellation of admission of our Ordinary Shares on AIM and this cancellation became effective on April
26, 2023.

Concurrently with the reverse split, and in order to continue meeting The NASDAQ
Stock Market LLC’s, or NASDAQ, minimum 500,000 publicly held shares requirement pursuant to Rule 5550(a)(4), on March 27, 2023 we
effected a ratio change in the number of Ordinary Shares represented by our Depositary Shares from 25 Ordinary Shares per Depositary Share
to five Ordinary Shares per Depositary Share.

On June 14, 2023, we held
our annual general meeting of shareholders, or June AGM, and our shareholders